Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of APX-115 in Healthy Male Volunteers
NCT03694041Phase 1Completed
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of isuzinaxib in diabetic kidney disease (DKD) (6 arms), sponsored by AptaBio Therapeutics Inc. Primary endpoints: Incidence of Treatment Emergent Adverse Events, Number of Clinically Significant Abnormal Findings from Vital Signs and 10 more. Started May 2018; status: completed.
02
Drugs
isuzinaxib
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT03694041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694041.